See the DrugPatentWatch profile for cosentyx

Side effects of Cosentyx (secukinumab) can vary in severity and impact an individual's quality of life. In some cases, these side effects may necessitate a dose reduction to minimize their impact. The decision to reduce the dose of Cosentyx is typically made on a case-by-case basis, taking into account the severity and frequency of the side effects, as well as the patient's overall health and treatment goals.

According to the prescribing information for Cosentyx [1], the most common side effects include injection site reactions, such as redness, swelling, and itching. These reactions are usually mild and temporary, but in some cases, they may be severe enough to require dose reduction. Other side effects that may warrant dose reduction include hypersensitivity reactions, such as anaphylaxis or angioedema [1].

The European Medicines Agency (EMA) recommends that patients who experience severe side effects, including hypersensitivity reactions, should discontinue Cosentyx and seek medical attention immediately [2]. In cases where the side effects are not severe but still require dose reduction, the patient's healthcare provider may recommend a temporary reduction in dose or a switch to an alternative treatment [2].

DrugPatentWatch.com reports that Cosentyx has a patent-protected period until 2027, which may impact the availability of alternative treatments for patients who experience side effects that require dose reduction [3]. However, it is essential to note that the availability of alternative treatments may vary depending on the country and region.

In conclusion, side effects that may require dose reduction of Cosentyx include injection site reactions, hypersensitivity reactions, and other severe side effects. The decision to reduce the dose of Cosentyx is typically made on a case-by-case basis, taking into account the severity and frequency of the side effects, as well as the patient's overall health and treatment goals.

Sources:

[1] Cosentyx Prescribing Information. (n.d.). Retrieved from <https://www.cosentyx.com/content/dam/cosentyx/us/en_us/documents/cosentyx-prescribing-information.pdf>

[2] European Medicines Agency. (n.d.). Cosentyx. Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx>

[3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/patent/US-9,245,444>